Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company's product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-38.18M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.74 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -51.44% |
| Return on Assets (Trailing 12 Months) | -36.31% |
| Current Ratio (Most Recent Fiscal Quarter) | 13.49 |
| Quick Ratio (Most Recent Fiscal Quarter) | 13.49 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.91 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.95 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.54 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.72 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.71 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 73.25M |
| Free Float | 61.09M |
| Market Capitalization | $466.58M |
| Average Volume (Last 20 Days) | 1.16M |
| Beta (Past 60 Months) | -0.81 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 13.93% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |